KR102324667B1 - 간성뇌증 치료용 스테로이드 화합물 - Google Patents

간성뇌증 치료용 스테로이드 화합물 Download PDF

Info

Publication number
KR102324667B1
KR102324667B1 KR1020167023426A KR20167023426A KR102324667B1 KR 102324667 B1 KR102324667 B1 KR 102324667B1 KR 1020167023426 A KR1020167023426 A KR 1020167023426A KR 20167023426 A KR20167023426 A KR 20167023426A KR 102324667 B1 KR102324667 B1 KR 102324667B1
Authority
KR
South Korea
Prior art keywords
ethynyl
hydroxyandrostan
oxime
rats
hepatic encephalopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167023426A
Other languages
English (en)
Korean (ko)
Other versions
KR20160105922A (ko
Inventor
매그너스 도베르스코그
한스 묄러
비센티 펠리포
토르비욘 백스트롬
Original Assignee
유메크린 코그니션 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유메크린 코그니션 에이비 filed Critical 유메크린 코그니션 에이비
Publication of KR20160105922A publication Critical patent/KR20160105922A/ko
Application granted granted Critical
Publication of KR102324667B1 publication Critical patent/KR102324667B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167023426A 2014-01-29 2015-01-14 간성뇌증 치료용 스테로이드 화합물 Active KR102324667B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450089 2014-01-29
SE1450089-6 2014-01-29
PCT/GB2015/050060 WO2015114308A1 (en) 2014-01-29 2015-01-14 Steroid compound for use in the treatment of hepatic encephalopathy

Publications (2)

Publication Number Publication Date
KR20160105922A KR20160105922A (ko) 2016-09-07
KR102324667B1 true KR102324667B1 (ko) 2021-11-10

Family

ID=52544513

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167023426A Active KR102324667B1 (ko) 2014-01-29 2015-01-14 간성뇌증 치료용 스테로이드 화합물

Country Status (25)

Country Link
US (3) US20160339040A1 (https=)
EP (1) EP3099306B1 (https=)
JP (1) JP6543633B2 (https=)
KR (1) KR102324667B1 (https=)
CN (2) CN113185566A (https=)
AU (1) AU2015212606B2 (https=)
BR (1) BR112016017620A2 (https=)
CA (1) CA2935015C (https=)
CY (1) CY1121464T1 (https=)
DK (1) DK3099306T3 (https=)
ES (1) ES2714563T3 (https=)
HR (1) HRP20190251T1 (https=)
HU (1) HUE042242T2 (https=)
IL (1) IL246496B (https=)
LT (1) LT3099306T (https=)
ME (1) ME03351B (https=)
MX (1) MX2016008851A (https=)
PL (1) PL3099306T3 (https=)
PT (1) PT3099306T (https=)
RS (1) RS58375B1 (https=)
RU (1) RU2684616C2 (https=)
SI (1) SI3099306T1 (https=)
SM (1) SMT201900133T1 (https=)
TR (1) TR201901687T4 (https=)
WO (1) WO2015114308A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2684616C2 (ru) 2014-01-29 2019-04-10 Умекрин Когнишн Аб Стероидное соединение для применения в лечении печеночной энцефалопатии
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
DK3668927T3 (da) 2017-09-12 2024-03-25 Eth Zuerich Transmembran ph-gradient polymersom til kvantificering af ammoniak i kropsvæsker
EP3716954A1 (en) * 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20230134958A1 (en) * 2021-10-29 2023-05-04 Umecrine Cognition Ab New medical treatment
EP4389129A1 (en) 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063128A1 (en) 2006-11-21 2008-05-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713061A (en) 1951-04-06 1955-07-12 Schering Ag 3-methyl androstanes
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3173932A (en) 1962-11-02 1965-03-16 American Cyanamid Co 15-substituted estra-1, 3, 5(10)-trienes
FR2685332A1 (fr) 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
AU756001B2 (en) 1998-03-11 2003-01-02 Umecrine Mood Ab Epiallopregnanolone in the treatment of CNS disorders
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
SI2153870T1 (sl) 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
HRP20200284T1 (hr) * 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
WO2015048818A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
RU2684616C2 (ru) 2014-01-29 2019-04-10 Умекрин Когнишн Аб Стероидное соединение для применения в лечении печеночной энцефалопатии

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063128A1 (en) 2006-11-21 2008-05-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Also Published As

Publication number Publication date
RS58375B1 (sr) 2019-03-29
CN113185566A (zh) 2021-07-30
CA2935015A1 (en) 2015-08-06
LT3099306T (lt) 2019-03-12
KR20160105922A (ko) 2016-09-07
JP6543633B2 (ja) 2019-07-10
PL3099306T3 (pl) 2019-06-28
US10342804B2 (en) 2019-07-09
SMT201900133T1 (it) 2019-05-10
SI3099306T1 (sl) 2019-03-29
BR112016017620A2 (pt) 2017-08-08
NZ721622A (en) 2020-11-27
AU2015212606A1 (en) 2016-07-14
CY1121464T1 (el) 2020-05-29
CN106163528A (zh) 2016-11-23
JP2017507113A (ja) 2017-03-16
EP3099306A1 (en) 2016-12-07
RU2684616C2 (ru) 2019-04-10
MX2016008851A (es) 2017-03-23
DK3099306T3 (en) 2019-03-18
RU2016127558A (ru) 2018-03-05
ES2714563T3 (es) 2019-05-29
TR201901687T4 (tr) 2019-02-21
HRP20190251T1 (hr) 2019-04-05
IL246496A0 (en) 2016-08-31
HUE042242T2 (hu) 2019-06-28
RU2016127558A3 (https=) 2018-09-27
PT3099306T (pt) 2019-03-21
WO2015114308A1 (en) 2015-08-06
US9801894B2 (en) 2017-10-31
US20180015103A1 (en) 2018-01-18
EP3099306B1 (en) 2018-12-12
ME03351B (me) 2019-10-20
AU2015212606B2 (en) 2019-11-21
WO2015114308A8 (en) 2016-07-21
IL246496B (en) 2019-09-26
CA2935015C (en) 2022-05-31
US20160339040A1 (en) 2016-11-24
US20170056416A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
KR102324667B1 (ko) 간성뇌증 치료용 스테로이드 화합물
JP2017507113A5 (https=)
JP6876047B2 (ja) ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物
WO2020028723A1 (en) Rbp4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
KR20170095302A (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
JP2023525570A (ja) 肝障害の併用処置
AU2017328999B2 (en) Combination of FXR agonists
US20260083704A1 (en) Lxr modulators with bicyclic core moiety for treating dyslipidemias
US20230212225A1 (en) Peptide compostions and methods for treating tauopathies
US20120010264A1 (en) Novel medicament for treating cognitive impairment
Brudeli et al. Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
NZ721622B2 (en) Steroid compound for use in the treatment of hepatic encephalopathy
HK1228753B (en) Steroid compound for use in the treatment of hepatic encephalopathy
HK1228753A1 (en) Steroid compound for use in the treatment of hepatic encephalopathy
WO2024173745A1 (en) Methods and compositions for treating huntington's disease and its symptoms

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000